Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A random survival forest-based pathomics signature classifies immunotherapy prognosis and profiles TIME and genomics in ES-SCLC patients

2 Oct 2024

Abstract excerpt

Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumor with high mortality, and only a limited subset of extensive-stage SCLC (ES-SCLC) patients demonstrate prolonged survival under chemoimmunotherapy, which warrants the exploration of reliable biomarkers. Herein, we built a machine learning-based model using pathomics features extracted from hematoxylin and eosin (H&E)-stained images to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39358575
DOI: 10.1007/s00262-024-03829-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A random survival forest-based pathomics signature classifies immunotherapy prognosis and profiles TIME and genomics in ES-SCLC patientsPMID 39358575Read ↗

Comprehensive genomic and spatial immune infiltration analysis of survival outliers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapy.Semantic proximity Read ↗

Construction of a Prognostic Model for Extensive-Stage Small Cell Lung Cancer Patients Undergoing Immune Therapy in Real-World Settings and Prediction of Treatment Efficacy Based on Response Status at Different Time PointsSemantic proximity Read ↗

Deciphering lung adenocarcinoma prognosis and immunotherapy response through an AI ‐driven stemness‐related gene signatureSemantic proximity Read ↗

Mutational Landscape and Treatment Response in Extensive-Stage Small-Cell Lung Cancer: A Single-Center Real-World Analysis.Semantic proximity Read ↗

Construction of an immunogenic cell death related gene signature: A new prognostic model for small cell lung cancerSemantic proximity Read ↗

Real-World Outcomes and Clinical Heterogeneity of First-Line Immunochemotherapy in Extensive-Stage Small-Cell Lung CancerSemantic proximity Read ↗

Decoding temporal heterogeneity in NSCLC through machine learning and prognostic model constructionSemantic proximity Read ↗

Prediction of 2-Year Mortality in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors Based on a Machine Learning AlgorithmSemantic proximity Read ↗

Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 studySemantic proximity Read ↗

Real-world survival outcomes to first-line chemoimmunotherapy and biomarker analysis in extensive-stage small-cell lung cancerSemantic proximity Read ↗

Radiomicsmetabolic signature profiles for advanced non-small cell lung cancer with chemoimmunotherapy by reflecting biological function and survivalSemantic proximity Read ↗

Survival prediction and molecular subtyping of squamous cell lung cancer based on network embedding.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.